SI-BONE (NASDAQ:SIBN) Posts Earnings Results

SI-BONE (NASDAQ:SIBN) posted its quarterly earnings results on Sunday. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03, MarketWatch Earnings reports. SI-BONE had a negative return on equity of 45.03% and a negative net margin of 61.67%.

SI-BONE stock traded down $2.88 during mid-day trading on Tuesday, hitting $33.08. The company’s stock had a trading volume of 25,822 shares, compared to its average volume of 287,842. The firm has a market capitalization of $1.09 billion, a PE ratio of -20.62 and a beta of 1.41. SI-BONE has a 1 year low of $14.37 and a 1 year high of $36.78. The company has a current ratio of 12.65, a quick ratio of 12.22 and a debt-to-equity ratio of 0.39. The stock’s fifty day moving average is $33.10 and its two-hundred day moving average is $28.78.

SIBN has been the subject of a number of analyst reports. Canaccord Genuity upped their price target on SI-BONE from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC upped their price target on SI-BONE from $34.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered SI-BONE from a “hold” rating to a “sell” rating in a research report on Friday, March 12th. Truist Securities upped their price target on SI-BONE from $35.00 to $43.00 in a research report on Tuesday. Finally, JMP Securities upped their price target on SI-BONE from $27.00 to $35.00 and gave the company an “outperform” rating in a research report on Friday, January 8th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. SI-BONE presently has an average rating of “Buy” and an average price target of $36.63.

In other news, CEO Jeffrey W. Dunn sold 40,000 shares of the firm’s stock in a transaction on Friday, March 5th. The stock was sold at an average price of $28.65, for a total transaction of $1,146,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Laura Francis sold 18,358 shares of the firm’s stock in a transaction on Thursday, March 18th. The stock was sold at an average price of $33.34, for a total value of $612,055.72. Following the transaction, the chief financial officer now owns 197,471 shares of the company’s stock, valued at $6,583,683.14. The disclosure for this sale can be found here. Insiders sold 1,067,472 shares of company stock valued at $32,658,438 over the last quarter. 15.50% of the stock is currently owned by company insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Featured Article: Lock-Up Period Expiration

Earnings History for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.